
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Many Capabilities Need to Be Evaluated by the Sponsor or CRO When it Chooses a Central IRB






